Decentralized clinical trials market seen reaching $35.62B by 2035

The global decentralized clinical trials market is projected to rise from $10.13 billion in 2025 to $35.62 billion by 2035, driven by regulatory support, recruitment cost pressure and broader use of connected sensors. Market Research Future says the sector is moving from pilot projects to mainstream trial operations as sponsors seek faster enrollment and more patient-friendly study designs.

Why it matters: - Decentralized clinical trials are moving from niche pilots to a larger operating model for drug and device development. - The shift could lower recruitment friction, reduce site burden and expand access to patients outside major research centers. - The market’s growth reflects a broader move toward patient-centered trial execution.

What happened: - Market Research Future projected the global decentralized clinical trials market will grow from USD 10.13 billion in 2025 to USD 35.62 billion by 2035. - The forecast implies a 13.4% CAGR for the 2026–2035 period. - The first year of the forecast period, 2026, is valued at USD 11.49 billion. - The report cites regulatory endorsement, recruitment cost pressure and connected sensor maturity as the main growth drivers. - The report is available through the full report.

The details: - FDA final guidance issued in September 2024 gave sponsors a clearer path for decentralized elements, including remote visits and direct-to-patient shipment. - Approximately 32% of Phase III trial expenses go to patient recruitment. - Decentralized enrollment can reduce time-to-full-enrollment by 22% to 29% for qualifying protocols. - Hardware cost per enrolled patient fell 41% between 2021 and 2025. - Wearable-derived endpoints are now used in a limited set of indications, including gait in neuromuscular disease, nocturnal scratch in atopic dermatitis and ambulatory rhythm in cardiology. - The Digital Medicine Society’s evidentiary framework shortened the qualification cycle by an estimated eight months. - Average Phase III protocols now include 263 discrete procedures, up nearly a third over the past decade.

• By study design, interventional trials held the largest share in 2025 at 62.4%.
• Observational trials accounted for 29.1% of the market in 2025.
• Expanded access made up 8.5% of the market in 2025.
• By component, cloud-based platforms led with a 38.4% share in 2025.
• Connected devices and wearables were the fastest-growing component, with a projected 15.9% CAGR from 2026 to 2035.
• Software for eConsent, ePRO and eCOA reached USD 2.34 billion in 2025.
• Services and site enablement reached USD 2.41 billion in 2025.
• By therapeutic application, oncology led with a 31.2% share in 2025.
• Neurology held 18.6% share in 2025.
• Cardiology held 16.4% share in 2025.
• Infectious diseases held 12.8% share in 2025.
• By end user, pharmaceutical and biotech sponsors accounted for 54.6% of the market in 2025.
• Contract research organizations were the fastest-growing end user, with a projected 14.7% CAGR.
• Medical device companies represented USD 1.02 billion in 2025.

• Academic and research institutes held 9.8% share in 2025.

• Asia-Pacific led the market in 2025 with about 34.8% share.

• North America is projected to be the fastest-growing region, with a 15.1% CAGR from 2026 to 2035.
• Europe held 22.6% share in 2025 and was valued at USD 2.29 billion.
• South America held 5.1% share in 2025.

• The Middle East and Africa region is projected to grow at a 14.6% CAGR from 2026 to 2035.

• The market is moderately concentrated, with the top five vendors holding roughly 41% to 47% of revenue.

• IQVIA acquired a European home-health nursing network in June 2024 to bring mobile visit delivery in-house.
• Medidata extended Sensor Cloud in March 2025 to support more than 190 validated device models.
• ICON launched a hybrid trial design accelerator in February 2025.
• Medable announced a multi-year enterprise agreement in October 2024 covering 40+ protocols with a top-10 sponsor.
• Other named players include Oracle Life Sciences, Parexel, Clario, Science 37, THREAD Research, Castor and Veeva Systems.
• FDA published final guidance on decentralized elements in September 2024.
• EMA issued a reflection paper on remote source data verification in January 2025.
• CDSCO India formalized acceptance of electronic informed consent for specified trial categories in April 2025.

Between the lines: - Regulators are making decentralized trial methods easier to defend, which lowers one of the biggest barriers to adoption. - The business case is also strengthening because recruitment is expensive and protocol complexity is rising. - The vendor market still has room for specialists, even as larger CROs push to bundle more services and technology. - Regional differences matter: Asia-Pacific leads on scale, North America on growth, and Europe on compliance-heavy infrastructure.

What's next: - The report expects payer-linked real-world evidence, emerging-market trial localization and federated analytics to open additional use cases. - Rare-disease registry integration could shorten enrollment timelines. - Decentralized post-approval safety surveillance may become an easier entry point for sponsors testing distributed operations. - Market Research Future projects the market will reach USD 35.62 billion by 2035 as decentralized models become more embedded in clinical development.